Immunotherapy for colorectal cancer: where are we heading?

被引：85

作者：

Basile, Debora ^{[1
]}

Garattini, Silvio Ken ^{[1
]}

Bonotto, Marta ^{[1
]}

Ongaro, Elena ^{[1
]}

Casagrande, Mariaelena ^{[1
]}

Cattaneo, Monica ^{[1
]}

Fanotto, Valentina ^{[1
]}

De Carlo, Elisa ^{[1
]}

Loupakis, Fotios ^{[3
]}

Urbano, Federica ^{[2
,3
]}

Negri, Francesca V. ^{[4
]}

Pella, Nicoletta ^{[1
]}

Russano, Marco ^{[5
]}

Brunetti, Oronzo ^{[6
]}

Scartozzi, Mario ^{[7
,8
]}

Santini, Daniele ^{[5
]}

Silvestris, Nicola ^{[6
]}

Gardini, Andrea Casadei ^{[9
]}

Puzzoni, Marco ^{[7
,8
]}

Calvetti, Lorenzo ^{[10
]}

Cardarelli, Nadia ^{[10
]}

Aprile, Giuseppe ^{[1
,10
]}

机构：

[1] Univ & Gen Hosp, Dept Oncol, Udine, Italy

[2] Univ Roma La Sapienza, Dept Dermatol Sci Radiol & Pathol, Med Oncol B, Rome, Italy

[3] IRCCS, IOV, Dept Med & Expt Oncol, Med Oncol 1, Padua, Italy

[4] Univ Hosp, Dept Oncol, Parma, Italy

[5] Campus Biomed Univ, Med Oncol, Rome, Italy

[6] Natl Canc Inst IRCCS Giovanni Paolo II, Med Oncol Unit, Bari, Italy

[7] Univ Hosp, Med Oncol, Cagliari, Italy

[8] Univ Cagliari, Cagliari, Italy

[9] IRCCS, IRST, Dept Med Oncol, Meldola, Italy

[10] San Bortolo Gen Hosp, Dept Oncol, ULSS8 Berica East Dist, Vicenza, Italy

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2017年 / 17卷 / 06期

关键词：

Immunotherapy; colorectal cancer; PD-L1; MSI; pembrolizumab; atezolizumab; DEFICIENT MISMATCH REPAIR; MOLECULAR SUBTYPES; T-CELLS; FUSOBACTERIUM-NUCLEATUM; TUMOR MICROENVIRONMENT; IMMUNE CHECKPOINTS; IMMUNOSCORE; SURVIVAL; CLASSIFICATION; MACROPHAGES;

D O I：

10.1080/14712598.2017.1315405

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Introduction: In the last few years, significant advances in molecular biology have provided new therapeutic options for colorectal cancer (CRC). The development of new drugs that target the immune response to cancer cells seems very promising and has already been established for other tumor types. In particular, the use of immune checkpoint inhibitors seems to be an encouraging immunotherapeutic strategy. Areas covered: In this review, the authors provide an update of the current evidence related to this topic, though most immunotherapies are still in early-phase clinical trials for CRC. To understand the key role of immunotherapy in CRC, the authors discuss the delicate balance between immune-stimulating and immune-suppressive networks that occur in the tumor microenvironment. Expert opinion: Modulation of the immune system through checkpoint inhibition is an emerging approach in CRC therapy. Nevertheless, selection criteria that could enable the identification of patients who may benefit from these agents are necessary. Furthermore, potential prognostic and predictive immune biomarkers based on immune and molecular classifications have been proposed. As expected, additional studies are required to develop biomarkers, effective therapeutic strategies and novel combinations to overcome immune escape resistance and enhance effector response.

引用

页码：709 / 721

页数：13

共 95 条

[1] Global patterns and trends in colorectal cancer incidence and mortality [J].